A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

Neville K. Kisalu, Azza H. Idris, Connor Weidle, Yevel Flores-Garcia, Barbara J. Flynn, Brandon Wilder, Sean Murphy, Arne Schön, Ernesto Freire, Joseph R. Francica, Alex B. Miller, Jason Gregory, Sandra March, Hua Xin Liao, Barton F. Haynes, Kevin Wiehe, Ashley M. Trama, Kevin O. Saunders, Morgan A. Gladden, Anthony Monroe & 18 others Mattia Bonsignori, Masaru Kanekiyo, Adam K. Wheatley, Adrian B. McDermott, S. Katie Farney, Gwo Yu Chuang, Baoshan Zhang, Natasha Kc, Sumana Chakravarty, Peter D. Kwong, Photini Sinnis, Sangeeta N. Bhatia, Stefan H.I. Kappe, B. Kim Lee Sim, Stephen L. Hoffman, Fidel Zavala, Marie Pancera, Robert A. Seder

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) from several subjects immunized with an attenuated Pf whole-sporozoite (SPZ) vaccine (Sanaria PfSPZ Vaccine). Passive transfer of one of these antibodies, monoclonal antibody CIS43, conferred high-level, sterile protection in two different mouse models of malaria infection. The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif. The demonstration that CIS43 is highly effective for passive prevention of malaria has potential application for use in travelers, military personnel and elimination campaigns and identifies a new and conserved site of vulnerability on PfCSP for next-generation rational vaccine design.

Original languageEnglish (US)
Pages (from-to)408-416
Number of pages9
JournalNature medicine
Volume24
Issue number4
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Malaria
Parasites
Vaccines
Monoclonal Antibodies
Epitopes
Plasmodium falciparum
Infection
Proteins
Sporozoites
Passive Immunization
Military Personnel
Molecular interactions
Antibodies
Stoichiometry
Antigens
Demonstrations
Crystal structure
Personnel

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kisalu, N. K., Idris, A. H., Weidle, C., Flores-Garcia, Y., Flynn, B. J., Wilder, B., ... Seder, R. A. (2018). A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature medicine, 24(4), 408-416. https://doi.org/10.1038/nm.4512

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. / Kisalu, Neville K.; Idris, Azza H.; Weidle, Connor; Flores-Garcia, Yevel; Flynn, Barbara J.; Wilder, Brandon; Murphy, Sean; Schön, Arne; Freire, Ernesto; Francica, Joseph R.; Miller, Alex B.; Gregory, Jason; March, Sandra; Liao, Hua Xin; Haynes, Barton F.; Wiehe, Kevin; Trama, Ashley M.; Saunders, Kevin O.; Gladden, Morgan A.; Monroe, Anthony; Bonsignori, Mattia; Kanekiyo, Masaru; Wheatley, Adam K.; McDermott, Adrian B.; Farney, S. Katie; Chuang, Gwo Yu; Zhang, Baoshan; Kc, Natasha; Chakravarty, Sumana; Kwong, Peter D.; Sinnis, Photini; Bhatia, Sangeeta N.; Kappe, Stefan H.I.; Sim, B. Kim Lee; Hoffman, Stephen L.; Zavala, Fidel; Pancera, Marie; Seder, Robert A.

In: Nature medicine, Vol. 24, No. 4, 01.05.2018, p. 408-416.

Research output: Contribution to journalArticle

Kisalu, NK, Idris, AH, Weidle, C, Flores-Garcia, Y, Flynn, BJ, Wilder, B, Murphy, S, Schön, A, Freire, E, Francica, JR, Miller, AB, Gregory, J, March, S, Liao, HX, Haynes, BF, Wiehe, K, Trama, AM, Saunders, KO, Gladden, MA, Monroe, A, Bonsignori, M, Kanekiyo, M, Wheatley, AK, McDermott, AB, Farney, SK, Chuang, GY, Zhang, B, Kc, N, Chakravarty, S, Kwong, PD, Sinnis, P, Bhatia, SN, Kappe, SHI, Sim, BKL, Hoffman, SL, Zavala, F, Pancera, M & Seder, RA 2018, 'A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite', Nature medicine, vol. 24, no. 4, pp. 408-416. https://doi.org/10.1038/nm.4512
Kisalu, Neville K. ; Idris, Azza H. ; Weidle, Connor ; Flores-Garcia, Yevel ; Flynn, Barbara J. ; Wilder, Brandon ; Murphy, Sean ; Schön, Arne ; Freire, Ernesto ; Francica, Joseph R. ; Miller, Alex B. ; Gregory, Jason ; March, Sandra ; Liao, Hua Xin ; Haynes, Barton F. ; Wiehe, Kevin ; Trama, Ashley M. ; Saunders, Kevin O. ; Gladden, Morgan A. ; Monroe, Anthony ; Bonsignori, Mattia ; Kanekiyo, Masaru ; Wheatley, Adam K. ; McDermott, Adrian B. ; Farney, S. Katie ; Chuang, Gwo Yu ; Zhang, Baoshan ; Kc, Natasha ; Chakravarty, Sumana ; Kwong, Peter D. ; Sinnis, Photini ; Bhatia, Sangeeta N. ; Kappe, Stefan H.I. ; Sim, B. Kim Lee ; Hoffman, Stephen L. ; Zavala, Fidel ; Pancera, Marie ; Seder, Robert A. / A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. In: Nature medicine. 2018 ; Vol. 24, No. 4. pp. 408-416.
@article{6194b06cb7424a4fb59030ff1c420c0f,
title = "A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite",
abstract = "Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) from several subjects immunized with an attenuated Pf whole-sporozoite (SPZ) vaccine (Sanaria PfSPZ Vaccine). Passive transfer of one of these antibodies, monoclonal antibody CIS43, conferred high-level, sterile protection in two different mouse models of malaria infection. The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif. The demonstration that CIS43 is highly effective for passive prevention of malaria has potential application for use in travelers, military personnel and elimination campaigns and identifies a new and conserved site of vulnerability on PfCSP for next-generation rational vaccine design.",
author = "Kisalu, {Neville K.} and Idris, {Azza H.} and Connor Weidle and Yevel Flores-Garcia and Flynn, {Barbara J.} and Brandon Wilder and Sean Murphy and Arne Sch{\"o}n and Ernesto Freire and Francica, {Joseph R.} and Miller, {Alex B.} and Jason Gregory and Sandra March and Liao, {Hua Xin} and Haynes, {Barton F.} and Kevin Wiehe and Trama, {Ashley M.} and Saunders, {Kevin O.} and Gladden, {Morgan A.} and Anthony Monroe and Mattia Bonsignori and Masaru Kanekiyo and Wheatley, {Adam K.} and McDermott, {Adrian B.} and Farney, {S. Katie} and Chuang, {Gwo Yu} and Baoshan Zhang and Natasha Kc and Sumana Chakravarty and Kwong, {Peter D.} and Photini Sinnis and Bhatia, {Sangeeta N.} and Kappe, {Stefan H.I.} and Sim, {B. Kim Lee} and Hoffman, {Stephen L.} and Fidel Zavala and Marie Pancera and Seder, {Robert A.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/nm.4512",
language = "English (US)",
volume = "24",
pages = "408--416",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

AU - Kisalu, Neville K.

AU - Idris, Azza H.

AU - Weidle, Connor

AU - Flores-Garcia, Yevel

AU - Flynn, Barbara J.

AU - Wilder, Brandon

AU - Murphy, Sean

AU - Schön, Arne

AU - Freire, Ernesto

AU - Francica, Joseph R.

AU - Miller, Alex B.

AU - Gregory, Jason

AU - March, Sandra

AU - Liao, Hua Xin

AU - Haynes, Barton F.

AU - Wiehe, Kevin

AU - Trama, Ashley M.

AU - Saunders, Kevin O.

AU - Gladden, Morgan A.

AU - Monroe, Anthony

AU - Bonsignori, Mattia

AU - Kanekiyo, Masaru

AU - Wheatley, Adam K.

AU - McDermott, Adrian B.

AU - Farney, S. Katie

AU - Chuang, Gwo Yu

AU - Zhang, Baoshan

AU - Kc, Natasha

AU - Chakravarty, Sumana

AU - Kwong, Peter D.

AU - Sinnis, Photini

AU - Bhatia, Sangeeta N.

AU - Kappe, Stefan H.I.

AU - Sim, B. Kim Lee

AU - Hoffman, Stephen L.

AU - Zavala, Fidel

AU - Pancera, Marie

AU - Seder, Robert A.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) from several subjects immunized with an attenuated Pf whole-sporozoite (SPZ) vaccine (Sanaria PfSPZ Vaccine). Passive transfer of one of these antibodies, monoclonal antibody CIS43, conferred high-level, sterile protection in two different mouse models of malaria infection. The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif. The demonstration that CIS43 is highly effective for passive prevention of malaria has potential application for use in travelers, military personnel and elimination campaigns and identifies a new and conserved site of vulnerability on PfCSP for next-generation rational vaccine design.

AB - Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) from several subjects immunized with an attenuated Pf whole-sporozoite (SPZ) vaccine (Sanaria PfSPZ Vaccine). Passive transfer of one of these antibodies, monoclonal antibody CIS43, conferred high-level, sterile protection in two different mouse models of malaria infection. The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif. The demonstration that CIS43 is highly effective for passive prevention of malaria has potential application for use in travelers, military personnel and elimination campaigns and identifies a new and conserved site of vulnerability on PfCSP for next-generation rational vaccine design.

UR - http://www.scopus.com/inward/record.url?scp=85045270080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045270080&partnerID=8YFLogxK

U2 - 10.1038/nm.4512

DO - 10.1038/nm.4512

M3 - Article

VL - 24

SP - 408

EP - 416

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -